Levothyroxine and Dacomitinib: Interaction Details

Brand names
Dacomitinib
Vizimpro
Levothyroxine
Levo-TLevoxylSynthroid +7 more
Dr. Brian Staiger, PharmD, BCPS

Medically reviewed by ⁠

Also reviewed by the HelloPharmacist Editorial Team Updated AI-assisted Details about this page
Share

Share this interaction

Levothyroxine

Brand names
  • Levo-T
  • Levoxyl
  • Synthroid
  • Tirosint
  • Unithroid
  • Levothroid
  • Euthyrox
  • Thyquidity
  • Ermeza
  • Tirosint SOL

What Happens When You Take Levothyroxine With Dacomitinib

What can happen when they are taken together (rated Moderate)

Increased risk of hypothyroidism

Interaction Deep Dive

A note from Dr. Brian Staiger If you’re a patient, this deep dive may be too technical, or bore you (or both). Read the plain-language explanation →

Patients receiving levothyroxine together with tyrosine kinase may face a heightened risk of hypothyroidism, so TSH levels in these individuals warrant close monitoring.21 When imatinib has been started in patients who had undergone thyroidectomy and were taking levothyroxine, thyrotropin (TSH) concentrations rose and hypothyroid symptoms appeared.

The precise mechanism behind this interaction has not been established; one proposed explanation is that imatinib, much like rifAMPin, induces levothyroxine , leading to higher serum TSH levels. For this reason, raising the levothyroxine dose is advisable when imatinib therapy is begun in hypothyroid patients maintained on levothyroxine replacement, particularly those who are post-thyroidectomy.

These patients should be watched for signs and symptoms of hypothyroidism, with routine assessment of serum thyroxine and TSH levels. Doubling the levothyroxine dose prior to starting imatinib may be considered.3

The Levothyroxine and Dacomitinib Interaction, Explained

Dacomitinib (Vizimpro) is a targeted lung cancer medicine, and levothyroxine replaces thyroid hormone your body doesn't make enough of. Medicines in the same family as dacomitinib have been linked to lower thyroid hormone levels in people taking levothyroxine. This can happen slowly over weeks. Your levothyroxine dose might stop being enough.

Watch for signs like feeling more tired, feeling cold, weight gain, constipation, or dry skin. The good news is that this is very manageable. Keep taking both medicines as prescribed. Your care team can check your thyroid levels and adjust your levothyroxine dose if needed.

Interaction: Tyrosine kinase (class effect, including dacomitinib) with levothyroxine may increase risk of hypothyroidism (reduced levothyroxine effectiveness).

  • Mechanism: Unknown. Best characterized with imatinib, where enhanced levothyroxine (rifampin-like ) is postulated. Data specific to dacomitinib are limited, so this is extrapolated from the TKI class.
  • Evidence: Probable. Onset: delayed. Severity: moderate.
  • Observed: elevated TSH and hypothyroid symptoms after TKI initiation, notably in post-thyroidectomy patients.
  • Management: Closely monitor TSH (and free T4) after starting the TKI and periodically thereafter. Assess for hypothyroid symptoms and titrate levothyroxine as needed. Preemptive dose increases are described for imatinib, but no fixed adjustment is established for dacomitinib.

See the 3 references behind this explanation ↓

From the HelloPharmacist Pharmacy Team

AI-assisted: written with AI from this pair’s record in our interaction database, and reviewed by the HelloPharmacist pharmacy team. Written .

How we build these pages · How we use AI · Our editorial policy

Why Levothyroxine and Dacomitinib Interact

The likely mechanism

Unknown

“Unknown” here means the studies and labels behind this record do not say how the interaction happens. It does not mean the interaction is unlikely.

How Drug Interactions Work Six short figures, about a minute: how one drug can raise or lower another’s level, or add to or cancel its effect. See how it works 

How to Manage the Levothyroxine and Dacomitinib Interaction

Your care team can manage this with simple monitoring:

  • Thyroid blood tests: Your team may check your TSH levels more closely after you start dacomitinib and keep checking over time.
  • Dose adjustment: If your levels change, your levothyroxine dose may need to be adjusted and individualized by your care team.

What you can do: Keep taking both medicines exactly as prescribed. Make sure your prescriber knows you take levothyroxine, especially if you've had thyroid surgery. Tell your pharmacist or doctor if you notice more tiredness, feeling cold, weight gain, or constipation.

Management is individual — confirm any change with your pharmacist or prescriber.

Questions for Your Pharmacist

  • Does my dose of Levothyroxine or Dacomitinib need adjusting while I take them together?
  • What symptoms should prompt me to call you or my prescriber right away?
  • Does the timing of my doses matter for this combination?
  • Is there anything you'd monitor while I'm on both?

Literature Reports

1 report from the published literature. Each one is headed by the title of the published study it comes from.

What these reports are. Short summaries of published evidence on this combination: clinical studies, case reports and, at times, the FDA prescribing information for one of the drugs. They support this interaction, but it does not rest on them alone. It can also rest on prescribing information not summarized here, or on what is expected from how these two drugs, and others in their drug classes, are known to work.

  1. Report 1 · Study title

    Imatinib induces hypothyroidism in patients receiving levothyroxine

    Patients who had undergone thyroidectomy and were maintained on levothyroxine therapy developed symptoms of hypothyroidism after imatinib therapy was started. Eleven patients (n=11) with stromal tumor and medullary thyroid carcinoma received imatinib for an average of 6 months.

    Of these, 8 patients had undergone total thyroidectomy and were also taking levothyroxine, while 3 patients had the thyroid in situ; all patients were euthyroid prior to imatinib treatment. On average, within 2 weeks of starting imatinib therapy, thyrotropin (TSH) levels rose to 384%+/-228% of the upper limit.

    Mean free thyroxine (fT4) and free tri-iodothyronine (fT3) values fell to 59% +/- 17% and 63% +/- 4% of the upper limits for fT4 and fT3, respectively, although they stayed within the reference range. These changes occurred only in the post-thyroidectomy patients, whereas patients with a normally functioning thyroid stayed euthyroid after imatinib therapy was initiated.

    In all post-thyroidectomy patients, the levothyroxine dose was increased in a stepwise manner to an average of 206% (range, 100% to 350%) of the pre-imatinib dose, which reversed hypothyroidism in only 3 patients. In the other post-thyroidectomy patients, hypothyroid symptoms resolved once imatinib was discontinued. The precise mechanism of this interaction between imatinib and levothyroxine was not established; however, the investigators excluded other likely causes of hypothyroidism and proposed that imatinib-mediated of levothyroxine may account for the hypothyroidism observed.3

Levothyroxine and Dacomitinib: Common Questions

How serious is the Levothyroxine and Dacomitinib interaction?

It is rated moderate. Can be significant — usually manageable with monitoring.

How is the Levothyroxine and Dacomitinib interaction managed?

Your care team can manage this with simple monitoring: Thyroid blood tests: Your team may check your TSH levels more closely after you start dacomitinib and keep checking over time. Dose adjustment: If your levels change, your levothyroxine dose may need to be adjusted and individualized by your care team. What you can do: Keep taking both medicines exactly as prescribed. Make sure your prescriber… Management is individual — always follow your own care team's guidance.

How quickly could this interaction happen?

The documented onset is "delayed". Effects tend to build up gradually over days to weeks.

How strong is the evidence for this interaction?

The evidence is graded "probable". Good supporting evidence, though not definitively proven.

Ask About the Levothyroxine and Dacomitinib Interaction

Ask in your own words about taking Levothyroxine and Dacomitinib together. The answer comes from this page’s interaction record and both drugs’ own information.

This box answers questions about this one combination only. For anything else about either drug, open its drug information page or ask a pharmacist.

Try:

AI answers from this page’s record and both drugs’ information, never the open internet. AI can make mistakes, so always check with your doctor or pharmacist.

References (3)

  1. Product Information: LEVO-T® oral tablets, levothyroxine sodium oral tablets. Neolpharma Inc, Caguas, PR, 2026. DailyMed
  2. Product Information: SYNTHROID(R) oral tablets, levothyroxine sodium oral tablets. AbbVie Inc (per FDA), North Chicago, IL, 2024. DailyMed
  3. de Groot JWB, Zonnenberg BA, Plukker JTM, et al: Imatinib induces hypothyroidism in patients receiving levothyroxine. Clin Pharmacol Ther 2005; 78:433-438. PubMed
Was this write-up helpful?

Other Serious Interactions of Levothyroxine and Dacomitinib

Also serious with Dacomitinib

Also serious with Levothyroxine

These Medications Also Interact With Supplements

Prescription drugs aren't the whole picture — herbal and dietary supplements can interact with them too. From the evidence-graded Natural Medicines database:

With Dacomitinib

With Levothyroxine

Check everything you take with our drug–supplement interaction checker.

Still Have Questions About This Combination?

Every question gets a real answer from a licensed pharmacist — free, as soon as they can.

About This Library

Built in-house, documented one interaction at a time. Our interaction database is not a complete list of every known interaction: a combination that isn't listed here hasn't been documented by us yet, which never means it's safe. Checking everything you take at once? Ask your pharmacist to review your full medication list. How we build and review it →

What Each Rating Means

Severity Levels

  • Contraindicated These should generally not be used together.
  • Major Potentially serious — often needs a change or close monitoring.
  • Moderate Can be significant — usually manageable with monitoring. This interaction.
  • Minor Usually limited clinical impact.

Evidence Grades

  • EstablishedWell documented — supported by controlled studies or strong clinical data.
  • ProbableGood supporting evidence, though not definitively proven. This interaction.
  • SuspectedSome evidence suggests this interaction, but it is not well established.
  • PossibleLimited or conflicting evidence; the interaction may occur.
  • TheoreticalExpected from how the drugs work, or from studies of similar drugs; this exact pair has little direct study.

How Soon It Shows

  • RapidEffects can appear quickly, often within about 24 hours of combining the drugs.
  • DelayedEffects tend to build up gradually over days to weeks. This interaction.
  • UnspecifiedThe timing of this interaction is not well characterized.

Ratings come from the documented interaction literature and are reviewed by a pharmacist. They describe the documented risk of the combination, not what will necessarily happen to you — your dose, timing, and health picture all matter.

Back to the answer
This information is for education, not a substitute for professional medical advice. Do not start, stop, or change any medication without talking to your pharmacist or prescriber.